Clip Money Inc. Reports First Quarter 2025 Results
First Quarter Financial 2025 Highlights:
Network & Customer Highlights:
'We are pleased with our Q1 results, which position Clip for continued growth through 2025. The ongoing addition of store locations by our largest customers underscores our commitment to delivering value and reliable, differentiated service in a category that has long been underserved. We also achieved a key strategic milestone this quarter with the expansion of our network through a partnership with Green Dot. This partnership will add more than 4,000 over-the-counter deposit locations at major big-box retail stores, significantly enhancing the scale, convenience and capacity of the Clip Network. We believe this expansion further strengthens our value proposition to financial institutions, fintech's and businesses nationwide. '
Joseph Arrage (CEO & Co-Founder)
Corporate Update
The Company also announces that the board of directors has approved the grant of an aggregate of 965,000 restricted share units (the 'RSUs') and 27,500 options (the 'Options', and together with the RSUs, the 'Awards') to acquire common shares of the Company to certain directors, executives and employees of the Company to recognize their performance in 2024. The Awards will be issued on May 27, 2025.
All of the RSUs to be awarded to directors will vest 12 months after the date of the grant, and all of the RSUs to be awarded to executives and employees will vest over three years, with one-third vesting every 12 months after the date of the grant. The Options will have a three-year vesting period, with an exercise price equal to the closing market price of Clip Money's common shares on May 26, 2025, and will expire 10 years from the date of the grant. The RSUs and Options will be governed by the terms of the Company's amended and restated omnibus equity incentive plan, under which an aggregate of 10,516,419 Common Shares are issuable.
Additional Information
The Company's interim condensed consolidated financial statements, notes to financial statements, and management's discussion and analysis for the three months ended March 31, 2025 are available on the Company's SEDAR+ profile at www.sedarplus.ca. Unless otherwise indicated, all references to '$' in this press release refer to U.S. dollars.
Forward‐Looking Statements
This news release may contain forward‐looking statements (within the meaning of applicable securities laws) which reflect the Company's current expectations regarding future events. Forward-looking statements are identified by words such as 'believe', 'anticipate', 'project', 'expect', 'intend', 'plan', 'will', 'may', 'estimate' and other similar expressions. These statements are based on the Company's expectations, estimates, forecasts and projections and include, without limitation, statements regarding the future success of the Company's business.
The forward-looking statements in this news release are based on certain assumptions. The forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, these forward-looking statements are made as of the date of this news release and, except as expressly required by applicable law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
About Clip Money Inc.
Clip operates a multi-bank self-service deposit system for businesses through the Clip Money network that gives users the capability of making deposits outside of their bank branch at top retailers and shopping malls. Rather than having to go to their personal bank branch or using a cash pickup service, businesses can deposit their cash at any ClipDrop Box or ClipATM located near them. After being deposited, the funds will automatically be credited to the business' bank account, usually within one business day. The Company combines functional hardware, an intuitive mobile app and an innovative cloud-based transaction engine that maximizes business-banking transactions. Combined with mobile user applications, Clip offers a cost-effective and convenient solution for business banking deposits in metropolitan statistical areas across Canada and the United States. For more information about the Company, visit www.clipmoney.com.
For further information, please contact:
Joseph Arrage
Chief Executive Officer
tel: 844-593-2547
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
a few seconds ago
- New York Times
What Connor McDavid's next contract could tell us about the Oilers
Since August 1988, when Wayne Gretzky was sold in what was called a trade at the time, the city of Edmonton has doubled in size. The city's airport has gone through several upgrades, to the point any awkward moments at #YEG are unlikely. Perhaps more importantly, the Edmonton Oilers are one of the richest franchises in the NHL, with a fan base so devoted that the city itself is more an Oilers town than a hockey town. Advertisement This summer, the city has been mostly calm when discussing the potential next contract for Connor McDavid, the team's captain and best player. Fortunately for modern fans of the team, those economic and population changes since 1988 mean an entirely different scenario for today. Insider reporting on the deal has been unusually vague about the details, making an observer suspicious about how much is actually known by even the most connected hockey reporters. It does appear a contract is likely to be signed, and that it will be a shorter deal than McDavid's previous agreement. Back in July 2017, he signed an eight-year extension for $100 million ($12.5 million annual average value); this time, some have him coming in around $16.5 million on a three- or four-year agreement. In the decade since arriving in Edmonton, the captain has delivered fantastic value in all 10 seasons. The franchise gets an enormous edge due to his presence on the roster, and no matter the cap hit on the new deal, his cap hit will continue to hold exceptional value. The player may prefer a shorter deal for two reasons. McDavid may not want a repeat of the last decade, a period when the team deployed elite talent at the top end but were never able to find enough support players of quality to win the Stanley Cup. The two recent trips to the Final represent progress while also making the superior depth of the Florida Panthers roster clear. Other NHL teams have consistently outperformed Oilers management. The second reason? McDavid may feel another three or four years devoted to the task of winning in Edmonton represents enough of a commitment to the organization. If he signs elsewhere in the fall of 2030, few could suggest he delivered less than his best while in an Oilers uniform. From the outside looking in, it looks like the lack of an answer to the Panthers' furious forecheck had a major impact on the result in the Stanley Cup Final. That includes deployment (Mattias Ekholm was not able to play at normal levels in Games 5 and 6) and execution — the players abandoned passes through the middle in favour of low-percentage outlets along the wall and alley-oop dumps to centre ice. Advertisement The Oilers looked like the older team, especially on the wings. A postmortem of the final also has to include mention of the goaltending, despite Stuart Skinner's strong performance against the Dallas Stars leading up to the Panthers series. General manager Stan Bowman has yet to address the goaltending, but the team's defence is recognized as being top-drawer. It is so deep that any trade in-season for a goaltender may include a defenceman as part of the assets out. The wingers will be younger, with rookies Matt Savoie and Ike Howard joined by veteran free-agent Andrew Mangiapane. Along with a healthy Zach Hyman and deadline addition Trent Frederic, coach Kris Knoblauch should be able to mix and match as needed through the regular season. Finding three lines that can outscore opponents at five-on-five will be key. The club has improved depth across the roster, from veteran forwards (such as Curtis Lazar) to wild-card European additions like David Tomasek and Atro Leppänen. The deadline deal for Jake Walman was a big part of the upgrade, and Bowman did move the needle this summer. A guess on goaltending: the organization gives Skinner and Calvin Pickard most of the regular season (to the deadline) in order to show consistency. At that time, or before, management likely makes a move. The Oilers may opt to carry a 22-man roster (one short of the maximum) in an effort to optimize the trade deadline. A list of possible additions at that time include names like right wing Alex Tuch (Buffalo Sabres), left wing Adrian Kempe (Los Angeles Kings), defenceman Jamie Oleksiak (Seattle Kraken) and goaltender Filip Gustavsson (Minnesota Wild). There is also the added urgency that comes from the foundation of this team (McDavid, Leon Draisaitl, Darnell Nurse) aging out of their peak years and reaching their 30s over the next few seasons. McDavid has been carrying this roster forever — he may not be able to reach previous dizzying heights with the same consistency, and injuries will become a bigger factor. The anxiety some Oilers fans feel about the future is real, and adding young talent like Savoie and Howard is vital. Advertisement The next McDavid contract will give fans an indication of how much additional time the captain wishes to devote to a management group that has consistently run out of sync with the cutting-edge GMs in the league. He's held up his end of the bargain; it's time for the organization to stand and deliver. When Peter Chiarelli arrived in 2015, he traded for a starting goaltender (Cam Talbot), signed a top-flight defenceman (Andrej Sekera) and then invested heavily in riskier assets like Griffin Reinhart and Milan Lucic. The Oilers were a team badly in need of a stronger farm system, but Chiarelli neither committed to a full rebuild nor optimized McDavid's entry deal in an effort to win it all early. Ken Holland got a lot closer, but like Chiarelli, bled young assets like they were a constantly renewing resource. His time in Edmonton will be remembered as a mixture of inspired acquisitions (Hyman, Ekholm) and baffling deals (the Duncan Keith trade) that led directly to more baffling deals (the Darnell Nurse contract). McDavid's frustration after the Final likely had much to do with the Panthers' impressive efforts against the Oilers' outlet attempts. Some of the vexation may also come from the decade of curious roster decisions that consistently left Edmonton poorer. If McDavid has expressed bewilderment in regard to Oilers' management being unable to compete for talent at the highest levels, he is justified in doing so. If a short-term contract is a result of that frustration, it may clarify things and possibly put an end to walkabout trade ideas and front-office gaffes that cost real talent. This isn't Stan Bowman's fault, but it is his problem. The length of McDavid's deal starts the clock on what could be his final seasons in Edmonton. Spot the pattern. Connect the terms Find the hidden link between sports terms Play today's puzzle
Yahoo
29 minutes ago
- Yahoo
Snap Stock Plunged After Earnings. Buy the Dip?
Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
